DE68928243D1 - Aufnahmesystem für menschliche hoch-affine Neurotransmitter - Google Patents

Aufnahmesystem für menschliche hoch-affine Neurotransmitter

Info

Publication number
DE68928243D1
DE68928243D1 DE68928243T DE68928243T DE68928243D1 DE 68928243 D1 DE68928243 D1 DE 68928243D1 DE 68928243 T DE68928243 T DE 68928243T DE 68928243 T DE68928243 T DE 68928243T DE 68928243 D1 DE68928243 D1 DE 68928243D1
Authority
DE
Germany
Prior art keywords
neurotransmitters
affinity
recording system
human high
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE68928243T
Other languages
English (en)
Other versions
DE68928243T2 (de
Inventor
Dominic M Lam
Albert S Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26956748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68928243(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/274,328 external-priority patent/US5188954A/en
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of DE68928243D1 publication Critical patent/DE68928243D1/de
Application granted granted Critical
Publication of DE68928243T2 publication Critical patent/DE68928243T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
DE68928243T 1988-11-21 1989-11-21 Aufnahmesystem für menschliche hoch-affine Neurotransmitter Revoked DE68928243T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/274,328 US5188954A (en) 1988-11-21 1988-11-21 High-affinity human serotonin uptake system
US07/342,238 US5225323A (en) 1988-11-21 1989-04-24 Human high-affinity neurotransmitter uptake system
PCT/US1989/005358 WO1990006047A2 (en) 1988-11-21 1989-11-21 Human high-affinity neurotransmitter uptake system

Publications (2)

Publication Number Publication Date
DE68928243D1 true DE68928243D1 (de) 1997-09-11
DE68928243T2 DE68928243T2 (de) 1998-01-15

Family

ID=26956748

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928243T Revoked DE68928243T2 (de) 1988-11-21 1989-11-21 Aufnahmesystem für menschliche hoch-affine Neurotransmitter

Country Status (8)

Country Link
US (2) US5225323A (de)
EP (1) EP0502845B1 (de)
JP (1) JP2902106B2 (de)
KR (1) KR920700046A (de)
AU (1) AU637608B2 (de)
CA (1) CA1339694C (de)
DE (1) DE68928243T2 (de)
WO (1) WO1990006047A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008214A1 (en) * 1991-10-24 1993-04-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services cDNA ENCODING THE COCAINE-SENSITIVE BOVINE DOPAMINE TRANSPORTER
US5552308A (en) * 1991-10-24 1996-09-03 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone of a rat serotonin transporter and protein encoded thereby
US6127131A (en) 1991-11-12 2000-10-03 Synaptic Pharmaceutical Corporation DNA encoding a glycine transporter and uses thereof
AU679432B2 (en) * 1991-11-12 1997-07-03 H. Lundbeck A/S DNA encoding a glycine transporter and uses thereof
US6225115B1 (en) 1992-03-04 2001-05-01 Synaptic Pharmaceutical Corporation DNA encoding taurine and GABA transporters and uses thereof
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
US5766848A (en) * 1993-01-04 1998-06-16 Synaptic Pharmaceutical Corporation Methods for identifying compounds which specifically bind a human betaine/GABA transporter
IL108499A (en) * 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5882926A (en) * 1993-10-20 1999-03-16 Oregon Health Sciences University Excitatory amino acid transporter gene and uses
US5912171A (en) * 1993-10-20 1999-06-15 Oregon Health Science University Amino acid transporters and uses
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
DE4343527A1 (de) * 1993-12-16 1995-06-22 Schering Ag Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung
GB9611192D0 (en) * 1996-05-29 1996-07-31 Medical Res Council Use
US5824486A (en) * 1996-05-31 1998-10-20 Allelix Neuroscience Inc. Glycine transporter-transfected cells and uses thereof
US5919653A (en) * 1996-08-20 1999-07-06 Allelix Neuroscience Inc. Nucleic acids encoding a human glycine transporter
US6008015A (en) 1997-04-11 1999-12-28 Allelix Neuroscience Inc. Glycine transporter
JP2002519064A (ja) * 1998-07-02 2002-07-02 インサイト・ファーマスーティカルズ・インコーポレイテッド 神経伝達関連タンパク質
GB9818890D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Novel compounds
EP1259610A2 (de) 2000-02-29 2002-11-27 Lexicon Genetics Incorporated Humane transporterproteine und ihre entsprechende nucleinsäuren
WO2001068871A2 (en) * 2000-03-13 2001-09-20 Lexicon Genetics Incorporated Human phospholipases and polynucleotides encoding the same
ES2238466T3 (es) 2000-07-21 2005-09-01 H. Lundbeck A/S Compuestos y su uso como inhibidores del transporte de glicina.
US7318917B2 (en) * 2002-09-06 2008-01-15 Vanderbilt University Rapid assays for neurotransmitter transporters
US7148027B2 (en) * 2003-02-25 2006-12-12 Emory University Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters
US7122500B2 (en) * 2003-09-22 2006-10-17 Exxonmobil Chemical Patents Inc. Molecular sieve catalyst composition, its making and use in conversion processes
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US20090275070A1 (en) * 2005-11-23 2009-11-05 Housey Gerard M Compounds and Methods of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators
US7947255B2 (en) * 2006-08-09 2011-05-24 Vanderbilt University Fluorescent substrates for neurotransmitter transporters
MY152979A (en) * 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
BRPI0907119A2 (pt) * 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
RU2571857C2 (ru) 2008-03-18 2015-12-20 Ново Нордиск А/С Стабилизированные по отношению к протеазам ацилированные аналоги инсулина
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
JP2012532177A (ja) * 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 熱及び振動安定性インスリン製剤
JP5675799B2 (ja) * 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR20160065126A (ko) 2013-10-07 2016-06-08 노보 노르디스크 에이/에스 인슐린 유사체의 신규한 유도체
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
HRP20221324T1 (hr) 2016-12-16 2022-12-23 Novo Nordisk A/S Farmaceutski pripravci koji sadrže inzulin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
AU4329489A (en) * 1988-09-30 1990-04-18 Australian Commercial Research & Development Limited Amino acid transport proteins, amino acid analogues, assay apparatus, uses thereof for treatment and diagnosis of cancer

Also Published As

Publication number Publication date
KR920700046A (ko) 1992-02-19
US5225323A (en) 1993-07-06
EP0502845A4 (de) 1992-04-21
EP0502845A1 (de) 1992-09-16
AU637608B2 (en) 1993-06-03
AU5350490A (en) 1990-06-26
US5424185A (en) 1995-06-13
JPH03504240A (ja) 1991-09-19
JP2902106B2 (ja) 1999-06-07
EP0502845B1 (de) 1997-08-06
WO1990006047A3 (en) 1990-09-20
CA1339694C (en) 1998-03-03
WO1990006047A2 (en) 1990-06-14
DE68928243T2 (de) 1998-01-15

Similar Documents

Publication Publication Date Title
DE68928243T2 (de) Aufnahmesystem für menschliche hoch-affine Neurotransmitter
DE68926803D1 (de) Informationsaufzeichnungssystem
DE69031203D1 (de) Datenaufzeichnungssystem
DE69127843D1 (de) Signalaufzeichnungssystem
DK313589A (da) Formastersystem
NO179594C (no) Opphengssystem for foringsrör
KR890700874A (ko) 텔레링크 시스템
DE68927036T2 (de) Toneffekt-System
DE68926203D1 (de) Aufzeichnungsgerät
DE68925462D1 (de) Semaphorarchitektur
KR900702427A (ko) 지식정보생성 시스템
DE68926429D1 (de) Anlagen-Diagnoseapparat
DE68929024T2 (de) Aufzeichnungsgerät
DE68912867D1 (de) Servoeinrichtung für Plattenspieler.
DE68928774D1 (de) Kamarasystem
NO178515C (no) Lasersystem
DE68918898D1 (de) Serienaufzeichnungsgerät.
DE68928214D1 (de) Dateneingabesystem
DE68929342D1 (de) Dateneingangssystem
AT389131B (de) Gleisanlage
KR900008339A (ko) 전자사진 기록장치
DK343889D0 (da) Hydrofonanlaeg eller -system
ATA254288A (de) Anschlussschienensystem
DK566788D0 (da) Laesesystem
KR890023584U (ko) 레코드 플레이어용 리피트 장치

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation